Macomics has a portfolio of modality agnostic therapeutic candidates, including antibody and small molecule programs, progressing towards the clinic.

Macomics will continue to expand its portfolio of validated targets in diseases where macrophages play a central role in aetiology, response to therapy, and patient outcomes.